US FDA grants EW-001 pre-IND meeting
Filed with ASX · · 4 pages · English
Summary by 6ix AI
This meeting will provide crucial feedback on manufacturing processes, non-clinical studies, and clinical trial design, helping to align AdAlta's plans with FDA expectations before formal submission. The pre-IND meeting is scheduled for early November, and the company will update the market based on the feedback received from the FDA.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from AdAlta
- Oribiotech deal validates AdAlta manufacturing strategy
- CAR-TCR Summit poster
- Bilingual BIOSeedin Investor Presentation
- BZDS1901 special access scheme launch in China
- Appendix 4G and Corporate Governance Statement
Later from AdAlta
- Date of AGM & Closing Date for Director Nominations
- China Representative Office opens
- EW-001 JDC milestone approvals
- RDTI receipt, Advanced Overseas Finding
- Quarterly Appendix 4C and Activities Report
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta